Novel catecholaminergic systems. Overview.
Goldstein
D S
DS
Clinical Neuroscience Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892-1424, USA.
D000818:Animals; D002394:Catechol O-Methyltransferase / Q000378:metabolism; D004298:Dopamine / Q000502:physiology*; D004837:Epinephrine / Q000378:metabolism*; D002393:Estrogens, Catechol / Q000378:metabolism*; D006801:Humans; D007980:Levodopa / Q000494:pharmacology / Q000502:physiology*; D009474:Neurons / Q000502:physiology; D018377:Neurotransmitter Agents / Q000502:physiology*; D009638:Norepinephrine / Q000378:metabolism*; D009928:Organ Specificity; D010625:Phenylethanolamine N-Methyltransferase / Q000378:metabolism; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
D002393:Estrogens, Catechol; D018377:Neurotransmitter Agents; D007980:Levodopa; D014446:Tyrosine 3-Monooxygenase; D010625:Phenylethanolamine N-Methyltransferase; D002394:Catechol O-Methyltransferase; D004298:Dopamine; D009638:Norepinephrine; D004837:Epinephrine